Vistogard (uridine triacetate)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Vistogard 10-gm single dose packets	May be subject to quantity limit

APPROVAL CRITERIA

Requests for Vistogard (uridine triacetate) may be approved if the following criteria are met:

I. Individual is using for the emergency treatment of fluorouracil or capecitabine overdose, regardless of the presence of symptoms;
OR
II. Individual exhibits early-onset, severe or life-threatening toxicity to fluorouracil or capecitabine, affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions;

AND
III. Therapy is initiated within 96 hours following the end of fluorouracil or capecitabine administration.

Requests for Vistogard may not be approved for the following:

I. For nonemergent treatment of adverse reactions associated with fluorouracil or capecitabine; **OR**
II. If Vistogard is initiated more than 96 hours following the end of fluorouracil or capecitabine administration.

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2022. URL: http://www.clinicalpharmacology.com. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. http://dailymed.nlm.nih.gov/dailymed/about.cfm. Accessed: March 29, 2022.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2022; Updated periodically.